Randomized Multicenter Evaluation of Quality of Life and Treatment Satisfaction in Type 2 Diabetes Patients Receiving Once-Weekly Trelagliptin Versus a Daily Dipeptidyl Peptidase-4 Inhibitor

INTRODUCTION: Dipeptidyl peptidase-4 (DPP-4) inhibitors are an established treatment in type 2 diabetes mellitus (T2DM). The objective of this study was to investigate differences in quality of life (QOL) and treatment satisfaction among treatment-naïve T2DM patients receiving once-weekly trelaglipt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Hitoshi, Suzaki, Yuki, Miyata, Yuko, Matsui, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612345/
https://www.ncbi.nlm.nih.gov/pubmed/31214997
http://dx.doi.org/10.1007/s13300-019-0643-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612345/
https://www.ncbi.nlm.nih.gov/pubmed/31214997
http://dx.doi.org/10.1007/s13300-019-0643-1

Ejemplares similares